Company news

Traws Pharma, Inc. news in 2025

Traws Pharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

December 17, 2025

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

November 13, 2025

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

October 30, 2025

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

October 22, 2025

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

October 14, 2025

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

October 6, 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

August 18, 2025

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

August 14, 2025

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

August 8, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025

Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025

Traws Pharma Announces Management Updates

March 28, 2025

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10: 00 AM ET

March 26, 2025

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

March 25, 2025

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

March 24, 2025

Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

March 21, 2025

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

March 3, 2025

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

February 28, 2025

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

January 22, 2025

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

January 9, 2025

Calls in 2025

Decks in 2025